SCHEMBL5075261

SCHEMBL5075261

NC(=O)c1ccc(-c2ccc(Cl)nc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 8/20 0.66
MKNK2 Q9HBH9 7/20 0.66
MAP4K4 O95819 5/20 0.56
PIK3CD O00329 1/20 0.53
NAPRT Q6XQN6 1/20 0.53
TDP1 Q9NUW8 1/20 0.49
CHEK2 O96017 2/20 0.49
RIPK1 Q13546 1/20 0.49
KCNQ3 O43525 1/20 0.49
KCNQ2 O43526 1/20 0.49
FYN P06241 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524193 0.84 NAPRT (0.67) NAPRTTDP1KCNQ3KCNQ2
SCHEMBL388168 0.84 NAPRT (0.67) NAPRTTDP1KCNQ3KCNQ2
SCHEMBL1109095 0.83 NAPRT (0.71) MKNK1MKNK2MAP4K4PIK3CDNAPRT
Hydrochloric Acid SCHEMBL3346497 0.82 NAPRT (0.64) NAPRTTDP1KCNQ3KCNQ2
Hydrochloric Acid SCHEMBL5013500 0.82 NAPRT (0.64) NAPRTTDP1KCNQ3KCNQ2
SCHEMBL1742846 0.81 NAPRT (0.53) MKNK1MKNK2PIK3CDNAPRTKCNQ3
SCHEMBL27417480 0.79 NAPRT (0.50) MKNK1MKNK2PIK3CDNAPRTKCNQ3
SCHEMBL24198706 0.77 NAPRT (0.49) MKNK1MKNK2MAP4K4PIK3CDNAPRT
SCHEMBL22575128 0.77 CSNK2A1 (0.52) PIK3CDNAPRTTDP1CHEK2KCNQ3
SCHEMBL2952147 0.77 KDM4E (0.50) MKNK1MKNK2NAPRTTDP1KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071768-B2 Alkylquinoline and alkylquinazoline kinase modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2011-12-06 US disclosed
CN-101242845-A Synergistic modulation of FLT3 kinase using a farnesyl transferase inhibitor JANSSEN PHARMACEUTICA NV (BE) 2008-08-13 CN disclosed
EP-1893214-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135629-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281772-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281772-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS FLT3, KIT, NTRK2 MKNK1 847/4885MKNK2 708/4885MAP4K4 285/4885
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines FLT3, MCL1, CDC42BPG MKNK1 689/4885MKNK2 620/4885MAP4K4 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.